Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for December 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

December 28, 2017

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

News Daily News

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

December 04, 2017

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

November 22, 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

Long-Awaited Hypertension Guidelines Released at AHA

News Conference News AHA 2017

Long-Awaited Hypertension Guidelines Released at AHA

November 13, 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

News Daily News

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Michael O'Riordan

October 10, 2017

Asymptomatic Carotid Artery Stenosis: When to Screen and When to Intervene

News Daily News

Asymptomatic Carotid Artery Stenosis: When to Screen and When to Intervene

October 05, 2017

Better Outcomes Seen for Stroke Patients Taken Directly to Thrombectomy Hospitals, but Protocols Lacking

News Daily News

Better Outcomes Seen for Stroke Patients Taken Directly to Thrombectomy Hospitals, but Protocols Lacking

Yael L. Maxwell

September 28, 2017

New Performance and Quality Metrics for STEMI and NSTEMI Care

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

September 08, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

FDA Deems ‘Field Action’ for Faulty IABPs a Class I Recall

August 07, 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

News Conference News SCCT 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Yael L. Maxwell

July 10, 2017

Catheter Kerfuffle: How Concerning Is Off-Label Use in Stroke Interventions?

News Features

Catheter Kerfuffle: How Concerning Is Off-Label Use in Stroke Interventions?

June 21, 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

June 19, 2017

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.